Together with our discovery of TAK‐228‐induced EGF and IFNβ contributing to PD‐L1 upregulation in bladder cancer cells adds to understanding multiple mechanisms modulating PD‐L1 during mTOR inhibition by TAK‐228. This evidence concerns the gene EGF and urinary bladder carcinoma.